24th Annual Scientific Meeting of the Australasian Society of Clinical Immunology and Allergy (ASCIA)
11-13 September 2013 • Perth Convention and Exhibition Centre (PCEC) • Western Australia

Held in conjunction with:
● ASCIA 2013 Postgraduate Immunology Course – Tuesday 10 September 2013
● ASCIA 2013 Allergy and Immunology Update for nurses, dietitians and other health professionals – Saturday 14 September 2013
● ASCIA 2013 Immunopathology Update – Saturday 14 September 2013

ASCIA is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand and is a member society of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and the World Allergy Organisation (WAO).
ASCIA gratefully acknowledges the generous support of the following sponsors:

**Diamond Sponsors**
- Abacus-ALS
- Abbott Nutrition
- Allergend
- Allergy & Anaphylaxis Australia
- Allergy New Zealand
- Alphapharm
- Asthma Australia
- AusEE
- AMSL/NZMS
- Baxter
- Bio-Strategy
- CSL Behring
- Diagnostic Solutions
- Ego Pharmaceuticals
- ESL Biosciences
- GlaxoSmithKline (GSK)
- HAE Australasia
- IDFA
- IDFNZ
- In Vitro Technologies
- Link
- Meda
- MedicAlert Foundation
- MSD
- National Asthma Council
- Neilmed
- Nestle Nutrition
- Novartis
- Nutricia Advanced Medical
- Nutricia Baby
- Octapharma
- Pathwest
- Shire
- Stallergenes
- Takeda
- TAMS
- ViroPharma

**Gold Sponsors**

**Exhibitors and other Sponsors**

Sponsors and exhibitors confirmed at the time of publishing this program book are as follows:

- Abacus-ALS
- Abbott Nutrition
- Allergend
- Allergy & Anaphylaxis Australia
- Allergy New Zealand
- Alphapharm
- Asthma Australia
- AusEE
- AMSL/NZMS
- Baxter
- Bio-Strategy
- CSL Behring
- Diagnostic Solutions
- Ego Pharmaceuticals
- ESL Biosciences
- GlaxoSmithKline (GSK)
- HAE Australasia
- IDFA
- IDFNZ
- In Vitro Technologies
- Link
- Meda
- MedicAlert Foundation
- MSD
- National Asthma Council
- Neilmed
- Nestle Nutrition
- Novartis
- Nutricia Advanced Medical
- Nutricia Baby
- Octapharma
- Pathwest
- Shire
- Stallergenes
- Takeda
- TAMS
- ViroPharma

*Note: The content of ASCIA 2013 is not influenced by its sponsors or exhibitors*
On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA) I warmly welcome you to Perth, Western Australia and to ASCIA 2013, the 24th Annual Scientific Meeting of the Australasian Society of Clinical Immunology and Allergy (ASCIA).

ASCIA is committed to providing excellence in continuing professional development for its members and other health professionals. In line with this commitment, ASCIA 2013 aims to provide an international standard of medical education in the areas of allergy and other immune diseases, including primary immunodeficiency and systemic autoimmune diseases.

I welcome you to ASCIA 2013 and trust that you will enjoy the fellowship of your ASCIA colleagues and all that Perth and Western Australia have to offer.

Clinical Associate Professor Richard Loh
ASCIA President

As Chair of the ASCIA 2013 organising committee, it is a great pleasure to welcome you to ASCIA 2013. The ASCIA 2013 Annual Scientific Meeting runs from Wednesday 11th to Friday 13th September and is being held in conjunction with:

- ASCIA Postgraduate Immunology Course on Tuesday 10th September.
- ASCIA 2013 Allergy and Immunology Update for nurses, dietitians and other health professionals on Saturday 14th September
- ASCIA 2013 Immunopathology Update on Saturday 14th September

The ASCIA 2013 scientific program will feature presentations by the following six keynote international speakers:

- Professor Abul Abbas (USA)
- Dr Linda Cox (USA)
- Professor Josep Dalmau (SPAIN, USA)
- Professor Raif Geha (USA)
- Professor Ruby Pawankar (JAPAN)
- Professor Harald Renz (GERMANY)

ASCIA 2013 also includes more than 40 other speakers and more than 40 Chairs from Australasia, including Professor Susan Prescott, who will present the 2013 Basten Oration.

A highlight of the ASCIA 2013 social program will be the Gala Dinner, to be held at the renowned State Reception Centre, part of Frasers Restaurant in Kings Park, with a spectacular view of Perth and the Swan River.

Situated beside the Swan River, Perth is like a living picture postcard, with outstanding views from Kings Park and Botanic Garden, one of the largest and most scenic inner city parks in the world. Perth is also Australia’s sunniest capital city, where you can enjoy the beach, relax in natural bushland, sample world class local wines and watch an ocean sunset within 30 minutes of the city centre. We hope that you will have the opportunity to enjoy many of these attractions during your visit to Perth for ASCIA 2013.

Dr Richard Nolan
ASCIA 2013 Chair
Program at a Glance

Tuesday 10 Sept
- PCEC Bellevue Ballroom 2
  - Postgraduate Immunology Course
  - Registration

Wednesday 11 Sept
- PCEC Bellevue Ballroom 2
  - ASM Day 1
  - Registration
  - JSAC Breakfast Forum

Thursday 12 Sept
- PCEC Bellevue Ballroom 2
  - ASM Day 2
  - Breakfast Immune Deficiency

Friday 13 Sept
- PCEC Bellevue Ballroom 2
  - ASM Day 3
  - Breakfast Neuro-immunology
  - Session 1: see full program for details

Saturday 14 Sept
- PCEC Riverview Room 4 Meeting Rooms 1-3
  - Immunopathology Update run concurrently with Allergy and Immunology Update

Registration
- Registration
- JSAC Breakfast Forum
- Registration

Breakfast
- Morning Tea

Morning Tea
- Morning Tea

Lunch
- Plenary - T lymphocyte activation and co-stimulation; Effector T cell subsets, Cytokines
- Symposium - Immunotherapy
- Session 2: see full program for details

Afternoon Tea
- Afternoon Tea

Afternoon Tea
- Clinical Grand Rounds Presentations
- Symposium - Drug Allergy
- Session 4: see program for details

Autoimmunity and immune mediated inflammatory diseases
- Plenary - Autoimmunity and immune mediated inflammatory diseases
- Poster discussion session

Welcome Function
- Welcome Function PCEC Bellevue Ballroom Foyer

Gala Dinner
- Gala Dinner PCEC Bellevue Ballroom Foyer

Closing Function
- Closing Function PCEC Bellevue Ballroom Foyer

Wine and Cheese Foyer adjacent to PCEC Riverview Room 4

Secretariat
GPO Box 3270 Sydney NSW 2001
Phone: 02 9254 5000
Fax: 02 9251 3552
Email: registration@ascia2013.com.au
Website: www.ascia2013.com.au

Registration and Abstract submission
GPO Box 450 Balgowlah NSW 2093
Ph: 0425 216 402
Fax: 02 9907 9773
Email: education@allergy.org.au

Sponsorship, Exhibition and Program Inquiries
### Postgraduate Immunology Course

**Tuesday 10 September 2013**

Perth Convention and Exhibition Centre: Bellevue Ballroom 2

**Course Director:** Professor Abul Abbas

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.30</td>
<td>Registration</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Introduction to the Immune System</td>
</tr>
<tr>
<td>09.00-10.00</td>
<td>Innate Immunity, Antigen Presentation</td>
</tr>
<tr>
<td><strong>10.00-10.30</strong></td>
<td>Morning Tea</td>
</tr>
<tr>
<td>10.30-11.30</td>
<td>T Lymphocyte Activation and Co-stimulation</td>
</tr>
<tr>
<td>11.30-12.30</td>
<td>Effector T Cell Subsets, Cytokines</td>
</tr>
<tr>
<td><strong>12.30-13.30</strong></td>
<td>Lunch</td>
</tr>
<tr>
<td>13.30-14.30</td>
<td>B Cells and Antibodies</td>
</tr>
<tr>
<td>14.30-15.30</td>
<td>Immunological Tolerance and Immune Regulation</td>
</tr>
<tr>
<td><strong>15.30-16.00</strong></td>
<td>Afternoon Tea</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td>Autoimmunity and Immune-Mediated Inflammatory Diseases</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

This course on Basic Immunology, with emphasis on immunologic diseases and therapeutic strategies, has been developed as an education program of the Federation of Clinical Immunology Societies (FOCIS).
### Day 1 Program

**Wednesday 11 September 2013**

**Perth Convention and Exhibition Centre: Bellevue Ballroom 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs/Annexes</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.45</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>07.15-08.45</td>
<td><strong>Breakfast – JSAC forum for supervisors and trainees</strong></td>
<td>Chairs: Dr Tiffany Hughes, Dr Melanie Wong, Dr Miriam Hurst</td>
</tr>
<tr>
<td>08.50-09.00</td>
<td><strong>Welcome from ASCIA President and ASCIA 2013 Chair</strong></td>
<td>A/Prof Richard Loh, Dr Richard Nolan</td>
</tr>
<tr>
<td>09.00-11.00</td>
<td><strong>Plenary – Origins of Allergy (Atopy)</strong></td>
<td>Chairs: Prof Dianne Campbell, Prof Connie Katelaris</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Basten Oration: Allergy and the NCD pandemic; the canary in the coal mine</td>
<td>Prof Susan Prescott</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Progress on the new frontier: epigenetics and allergy</td>
<td>Dr David Martino</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>New lessons from the microbial world</td>
<td>Prof Harald Renz</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Nutrition, diet and feeding practices in the origins of allergic disease</td>
<td>A/Prof Debra Palmer</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.30-13.00</td>
<td><strong>Plenary – Immune Deficiency, Genes and Autoimmunity</strong></td>
<td>Chairs: Dr Shannon Brothers, Dr Melanie Wong</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Approaches to the discovery of novel immunodeficiencies</td>
<td>Prof Raif Geha</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Balancing tolerance and autoimmunity: strategies for controlling harmful immune responses</td>
<td>Prof Abul Abbas</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Genetic testing for PID – what is available in Australasia</td>
<td>A/Prof Richard Loh</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td><strong>Symposium – Immunotherapy</strong></td>
<td>Chairs: Dr John Bandouvakis, Dr William Smith</td>
</tr>
<tr>
<td>14.00-14.45</td>
<td>Immune mechanisms of tolerance in SLIT and SCIT and differences</td>
<td>Dr Linda Cox</td>
</tr>
<tr>
<td>14.45-15.30</td>
<td>Venom immunotherapy… established cure or work in progress?</td>
<td>Prof Simon Brown</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>16.00-18.00</td>
<td><strong>Clinical Grand Rounds Presentations – presented by Advanced Trainees</strong></td>
<td>8 minutes have been allocated to each presentation and discussion of 15 cases. Refer to page 21 for program Chairs: Dr Michael O’Sullivan, Prof Pete Smith</td>
</tr>
<tr>
<td>18.00-19.00</td>
<td><strong>Welcome Function</strong></td>
<td>Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer</td>
</tr>
</tbody>
</table>
### Thursday 12 September 2013

**Perth Convention and Exhibition Centre: Bellevue Ballroom 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs/Administrator</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.45</td>
<td><strong>Registration</strong></td>
<td></td>
</tr>
<tr>
<td>07.00-08.45</td>
<td><strong>Breakfast – Immune Deficiency</strong></td>
<td>Dr Andrew Mclean-Tooke, Dr Jane Peake</td>
</tr>
<tr>
<td>07.15-07.45</td>
<td>Predicting adverse events following immune intervention</td>
<td>A/Prof Sean Riminton</td>
</tr>
<tr>
<td>07.45-08.15</td>
<td>Monitoring of CVID and patients with humoral immune deficiency</td>
<td>Dr Andrew Mclean-Tooke</td>
</tr>
<tr>
<td>08.15-08.45</td>
<td>Discussion of PID cases (3)</td>
<td>Prof Raif Geha</td>
</tr>
<tr>
<td>09.00-11.00</td>
<td><strong>Plenary – Origins of Allergy (organ specific disease)</strong></td>
<td>Dr Richard Nolan, Prof Susan Prescott</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Role of skin and mucosal barrier integrity in origins of allergic disease: preventive strategies</td>
<td>Prof Katie Allen</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Systems biology approaches to allergy and asthma pathogenesis</td>
<td>Dr Anthony Bosco</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Epithelia – immune cell interactions in airways inflammation: therapeutic targets</td>
<td>Prof Ruby Pawankar</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Progress with food allergy – experience with oral immunotherapy in practice</td>
<td>A/Prof Mimi Tang</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.30-12.30</td>
<td><strong>Symposium – Anaphylaxis</strong></td>
<td>Dr Miriam Hurst, Dr Preeti Joshi</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>New insights into pathogenesis of anaphylaxis</td>
<td>Dr Shelley Stone</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Anaphylaxis - unusual presentation and causes</td>
<td>Dr Ray Mullins</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-14.30</td>
<td><strong>ASCIA AGM</strong></td>
<td>A/Prof Richard Loh</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td><strong>ASCIA Education Update</strong></td>
<td>Dr Sam Mehr, Dr William Smith</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Allergy – a major Global Health Issue: World Allergy Organisation (WAO) White Book</strong></td>
<td>Prof Ruby Pawankar</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>16.00-17.30</td>
<td><strong>Poster Discussion Session</strong></td>
<td>10 minutes have been allocated to each presentation and discussion of 9 pre-selected posters</td>
</tr>
<tr>
<td>18.30-22.30</td>
<td><strong>Gala Dinner</strong></td>
<td>State Reception Centre, Frasers Restaurant, Kings Park</td>
</tr>
<tr>
<td></td>
<td>Buses depart from 18.00-18.30 from PCEC</td>
<td></td>
</tr>
</tbody>
</table>
## Day 3 Program

### Friday 13 September 2013

**Perth Convention and Exhibition Centre: Bellevue Ballroom 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.30</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>07.00-08.30</td>
<td><strong>Breakfast - Neuroimmunology</strong></td>
<td>Chairs: A/Prof Peter Hollingsworth, A/Prof Allan Kermode</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case presentations</td>
</tr>
<tr>
<td>08.45-10.30</td>
<td><strong>Plenary - Neuroimmunology</strong></td>
<td>Chairs: A/Prof Peter Hollingsworth, A/Prof Sean Riminton</td>
</tr>
<tr>
<td>08.45-09.30</td>
<td>Syndromes and synaptic mechanisms of autoimmune encephalitis</td>
<td>Prof Josep Dalmau</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Multiple sclerosis - controversies</td>
<td>A/Prof Allan Kermode</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Gene and environment interactions in multiple sclerosis</td>
<td>Dr David Nolan</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Plenary – Asthma</strong></td>
<td>Chairs: Dr Colin Somerville, Dr Celia Zubrinich</td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Inflammatory and non-inflammatory pathways in asthma – from bench to bedside</td>
<td>Prof Harald Renz</td>
</tr>
<tr>
<td>11.45-12.30</td>
<td>Asthma and immunotherapy</td>
<td>Dr Linda Cox</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Poster Discussion Session</strong></td>
<td>10 minutes have been allocated to each presentation and discussion of 9 pre-selected posters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: A/Prof Bob Heddle, Dr Peter Richmond</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-17.00</td>
<td><strong>Symposium – Drug Allergy</strong></td>
<td>Chairs: Dr Jeremy McComish, Dr Robert Pye</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Patch testing to drugs</td>
<td>Prof Elizabeth Phillips</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Beta-lactam testing: can we make it more effective?</td>
<td>Dr Jack Bourke</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Adverse reactions to anti-inflammatorises</td>
<td>Dr William Smith</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Closing Function / Wine and Cheese including CGR and Poster awards</strong></td>
<td>Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer</td>
</tr>
<tr>
<td>19.00</td>
<td><strong>Concurrent dinners including:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trainee and Consultants Dinner supported by CSL Behring, Parmelia Hilton Hotel Perth</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nurses Dinner supported by Stallergenes, Parmelia Hilton Hotel Perth</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session/Activity</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08.00-08.25</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.25-08.30</td>
<td>Welcome and Introduction                                                         Dr Christine Bundell, Monica Kemp</td>
<td></td>
</tr>
<tr>
<td>08.30-10.30</td>
<td><strong>Session 1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Anna Brusch, Dr Christine Bundell</td>
<td></td>
</tr>
<tr>
<td>08.30-09.15</td>
<td>Laboratory aspects of neuronal immunology                                        Prof Josep Dalmau</td>
<td></td>
</tr>
<tr>
<td>09.15-09.35</td>
<td>Case study: Anti NMDA R                                                          Dr Ben McGettigan</td>
<td></td>
</tr>
<tr>
<td>09.35-10.00</td>
<td>In vivo and in vitro testing for penicillin allergy                               Dr Jack Bourke</td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Immunopathology poster presentations (3)</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Session 2</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Meilyn Hew, Dr Melanie Wong</td>
<td></td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Post-natal development of the human innate immune system                         Dr Andrew Currie</td>
<td></td>
</tr>
<tr>
<td>11.45-12.15</td>
<td>Laboratory assessment of adult primary immune deficiency                          A/Prof David Fulcher</td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td>Case study                                                                       Dr Eliska Furlong</td>
<td></td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Session 3</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel: Dr Theo de Malmanche, Dr Tiffany Hughes, Gerhard Saueracker</td>
<td></td>
</tr>
<tr>
<td>13.30-14.30</td>
<td>Review of IIF slides (cytoplasmic including myositis on Hep2000 and LKS)</td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Isotype diversification of antibody responses and the role of follicular helper T cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Michael O’Sullivan                                                      Prof Martyn French</td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td><strong>Session 4</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Mark Goulding, Dr Miriam Hurst</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Clinical utility of testing for Th17 T cells                                      Adj A/Prof Michaela Lucas</td>
<td></td>
</tr>
<tr>
<td>16.00-16.20</td>
<td>Complement overview                                                              A/Prof Peter Hollingsworth</td>
<td></td>
</tr>
<tr>
<td>16.20-16.40</td>
<td>Mannose binding lectin overview                                                   Monica Kemp</td>
<td></td>
</tr>
<tr>
<td>16.40-17.00</td>
<td>C4 gene copy number                                                              A/Prof Campbell Witt</td>
<td></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Wine and Cheese</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08.00–08.45</td>
<td><strong>Registration</strong></td>
<td></td>
</tr>
<tr>
<td>08.50–11.00</td>
<td><strong>Session 1: Meeting Rooms 1-2</strong> Chairs: Rachael Dunn, Ingrid Roche</td>
<td></td>
</tr>
<tr>
<td>08.50-09.00</td>
<td><strong>Welcome and Introduction</strong> Rachael Dunn, Ingrid Roche</td>
<td></td>
</tr>
<tr>
<td>09.00–09.45</td>
<td>Gastrointestinal allergic disorders Prof Katie Allen</td>
<td></td>
</tr>
<tr>
<td>09.45-10.30</td>
<td>Specific oral tolerance induction [SOTI] A/Prof Mimi Tang</td>
<td></td>
</tr>
<tr>
<td><strong>10.30-11.00</strong></td>
<td><strong>Morning Tea</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Session 2: Meeting Rooms 1-2</strong> Chairs: Val Noble, Barbara Dennison</td>
<td></td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Management of food and needle phobias Jo Elliot</td>
<td></td>
</tr>
<tr>
<td>11.45-12.30</td>
<td>Management of anaphylaxis in teenagers and young adults Dr Adelaide Withers</td>
<td></td>
</tr>
<tr>
<td><strong>12.30-13.30</strong></td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Session 3 - Concurrent Program A: Meeting Rooms 1-2</strong> Chairs: Vicki O’Brien, Sacha Palmer</td>
<td></td>
</tr>
<tr>
<td>13.30-14.15</td>
<td>Primary immune deficiencies overview Dr Melanie Wong</td>
<td></td>
</tr>
<tr>
<td>14.15-15.00</td>
<td>Update on SC1g and HAE This session is supported by an unrestricted educational grant from <strong>ViroPharma</strong> Rachael Dunn</td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td><strong>Session 3 - Concurrent Program B: Meeting Room 3</strong> Chairs: Paula Brown, Evania Marlow</td>
<td></td>
</tr>
<tr>
<td>13.30-14.15</td>
<td>Food allergy research update A/Prof Debra Palmer</td>
<td></td>
</tr>
<tr>
<td>14.15-15.00</td>
<td>Dietitians toolbox: practicalities of managing clients with food allergy Merryn Netting Anna Richards Vicki McWilliam</td>
<td></td>
</tr>
<tr>
<td><strong>15.00-15.30</strong></td>
<td><strong>Afternoon Tea</strong></td>
<td></td>
</tr>
<tr>
<td>15.30-16.30</td>
<td><strong>Poster Discussion Session: Meeting Rooms 1-2</strong> Chairs: Pamela Burton, Kathy Beck</td>
<td></td>
</tr>
<tr>
<td>16.30-17.30</td>
<td><strong>Subcommittee Meeting – ASCIA Nurses: Meeting Rooms 1-2</strong> Chair: Rachael Dunn</td>
<td></td>
</tr>
<tr>
<td>16.30-17.30</td>
<td><strong>Subcommittee Meeting – ASCIA Dietitians: Meeting Room 3</strong> Chair: Ingrid Roche</td>
<td></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Wine and Cheese</strong> Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4</td>
<td></td>
</tr>
</tbody>
</table>
Professor Abul Abbas MBBS
President, Federation of Clinical Immunology Societies (FOCIS)
Professor and Chair, Department of Pathology, University of California, San Francisco (UCSF), USA

Professor Abbas completed his medical qualifications in New Delhi, India, before moving to the USA in 1970.

As well as being the current President of the Federation of Clinical Immunology Societies (FOCIS), Professor Abbas:
• continues to have an extensive commitment to training and fellowship programs
• has received over 20 awards/honours
• has been a representative on over 40 committees
• has authored or co-authored more than 175 publications and 4 medical textbooks
• is the co-editor of Annual Reviews of Pathology

Professor Abbas’s research is focused on immunological tolerance and autoimmunity. His laboratory is exploring the mechanisms that maintain tolerance to tissue and systemic self-antigens, and conditions that lead to the breakdown of self-tolerance and the development of autoimmunity. His laboratory is also analysing the roles of different cytokines and T-cell subsets in autoimmune disease, and in the function of regulatory T-cells.

At ASCIA 2013 Professor Abbas will be presenting as follows:
1. Postgraduate Immunology Course on Tuesday 10 September, 08.30-17.30
2. Balancing tolerance and autoimmunity: strategies for controlling harmful immune responses on Wednesday 11 September, 12.00-12.30

Professor Abbas's travel for ASCIA 2013 is supported by an educational grant from PathWest.

Dr Linda Cox MD FAAAAI FACAAI FACP
President, American Academy of Allergy, Asthma and Immunology (AAAAI)
Consultant, Allergy and Asthma Center, Fort Lauderdale, Florida USA

Dr Cox completed her medical qualifications in 1985 at the Northwestern University School of Medicine, Chicago, Illinois. This was followed by post graduate training in Allergy and Immunology at National Jewish Hospital, Denver, Colorado and Internal Medicine at University of Miami, Jackson Memorial Hospital, Miami, Florida.

As well as being the current President of the American Academy of Allergy, Asthma and Immunology (AAAAI), Dr Cox:
• has worked in private practice (solo) since 1992
• has received over 20 awards/honours
• is widely published in the field of allergy, asthma and immunology, particularly in the area of allergen immunotherapy
• is a current and past member of the several medical organisations Board of Directors and committees

Dr Cox’s research interests include sublingual immunotherapy safety and efficacy, comparative effectiveness of allergen immunotherapy and immunotherapy adherence

At ASCIA 2013 Dr Cox will be presenting as follows:
1. Immune mechanisms of tolerance in SLIT and SCIT and differences on Wednesday 11 September, 14.00-14.45
2. Asthma and immunotherapy on Friday 13 September, 11.45-12.30

Dr Cox’s travel for ASCIA 2013 is supported by an unrestricted educational grant from Stallergenes.

Professor Josep Dalmau MD PhD
Research Professor ICREA-IDIBAPS, Neurology, Hospital Clinic, Barcelona, Spain
Adjunct Professor of Neurology, University of Pennsylvania, Philadelphia, PA, USA

Professor Dalmau completed his medical education at the Autonoma University of Barcelona, Spain, gaining MD Hons in 1977 and PhD (Hons) in 1993. His postgraduate training in Neurology and Neuro-oncology was undertaken in Barcelona, Spain (University de la Sta. Cruz y San Pablo) and New York, USA (Colzias Laboratory of Neuro-Oncology, Sloan Kettering Institute; New York Hospital, Cornell University; Memorial Hospital for Cancer and Allied Diseases).

Professor Dalmau is widely published in the field of neuro-oncology and neuronal immunology, particularly in the area of autoimmune encephalitis and his research has led to important discoveries in this area.

At ASCIA 2013 Professor Dalmau will be presenting as follows:
1. Neuroimmunology case presentations (breakfast session) on Friday 13 September, 07.00-08.30
2. Syndromes and synaptic mechanisms of autoimmune encephalitis on Friday 13 September, 08.45-09.30

Professor Dalmau's travel for ASCIA 2013 is supported by an unrestricted educational grant from Stallergenes.
3. Laboratory aspects of neuronal immunology on Saturday 14 September, 08.30-09.15

Professor Dalmau’s travel for ASCIA 2013 is supported by unrestricted educational grants from CSL Behring (Annual Scientific Meeting) and ESL Biosciences (Immunopathology Update).

Professor Raif Geha MD
Chief, Division of Immunology, Boston Children’s Hospital, Boston MA, USA

Raif S. Geha, received his M.D. degree in 1969 from the American University of Beirut, Lebanon, and trained in Pediatrics and Immunology at Boston Children’s Hospital and Harvard Medical School. He is the James Gamble Professor of Pediatrics, Harvard Medical School and the Chief of the Division of Immunology, Allergy, Rheumatology and Dermatology Division at Boston Children’s Hospital. Dr. Geha’s research interests are in molecular and cellular mechanisms of primary immunodeficiencies and atopic dermatitis. Dr. Geha has received the Mead Johnson Award for Pediatric Research, the Kuwait Foundation for the Advancement of Sciences Prize, and the American Association of Immunologists Prize in Human Immunology Research. He is a member of the American Society of Clinical Investigation and has chaired the IUIS Committee on Immunodeficiency and the Clinical Immunology Society. He has contributed more than 365 original articles. His publications have appeared in Cell, Immunity, Nature, Nature Immunology, Molecular Cell, PNAS, Journal of Experimental Medicine, Journal of Clinical Investigation, Journal of Immunology and Journal of Allergy and Clinical Immunology. Dr. Geha has trained more than 120 postdoctoral fellows, many of whom are leaders in the fields of Allergy and Immunology.

At ASCIA 2013 Professor Geha will be presenting as follows:

1. Approaches to the discovery of novel immunodeficiencies on Wednesday 11 September, 11.30-12.00
2. Discussion of PID cases (breakfast session) on Thursday 12 September, 08.15-08.45

In addition to being the current President of the World Allergy Organization, Professor Pawankar:
• is widely published in the field of allergy, asthma and clinical immunology
• is an editor of several peer reviewed journals and books
• is a Member/Fellow of several allergy, asthma and clinical immunology societies serving also on their committees and boards
• has delivered several named lectures nationally and internationally
• has mentored several Japanese and international fellows in allergy and clinical immunology
• has received several national and international awards, including the Pravasi Bharatiya Samman (Overseas Indian Award), presented to her in 2010 by the President of India.

At ASCIA 2013 Professor Pawankar will be presenting as follows:

1. Epithelia – immune cell interactions in airways inflammation: therapeutic targets on Thursday 12 September, 10.00-10.30
2. Allergy – a major Global Health Issue: World Allergy Organisation (WAO) White Book on Thursday 12 September, 15.00-15.30

Professor Harald Renz MD
President, German Society of Allergology and Clinical Immunology
Professor of Laboratory Medicine, Philipps-University of Marburg, Germany
Specialist in Clinical Immunology and Allergology
Head, Department of Laboratory Medicine and Molecular Diagnostics, University Hospital Marburg, Germany

Professor Harald Renz completed his subspecialty training in Clinical Immunology and Allergology (1988-1995) in Marburg, Denver and Berlin.

His work on disease-related animal models has led to the development of mouse models for various disease-related phenotypes, including acute and chronic airway inflammation, airway remodelling, perinatal immune-development. He has further developed the concept of neuro-immune interaction in bronchial asthma and atopic dermatitis and is currently involved in the translation of the hygiene hypothesis from epidemiology to mechanism. He has published more than 200 original articles in peer-reviewed international journals, has contributed with 87 review articles and editorials and has edited 44 book chapters.
Professor Renz is the current President of the German Society of Allergology and Clinical Immunology. He also participates as an active member in several international scientific societies including AAAAI, EAACI and the ERS.

At ASCIA 2013 Professor Renz will be presenting as follows:

1. **New lessons from the microbial world** on Wednesday 11 September, 10.00-10.30
2. **Inflammatory and non-inflammatory pathways in asthma from bench to bedside** on Friday 13 September, 11.00-11.45

ASCIA 2013 Basten Oration

**Professor Susan Prescott**

MBBS BMedSc FRACP PhD

Winthrop Professor, School of Paediatrics and Child Health, University of Western Australia

Specialist Allergy and Immunology physician, Princess Margaret Hospital, Perth, Western Australia

Professor Susan Prescott’s contributions to research in the area of allergy and early immune development have been translated into novel concepts and led to a paradigm shift in the pathogenesis of allergic disease.

She is widely published (as an author or co-author of more than 200 scientific publications) and has been awarded eight fellowships including a Winston Churchill award. She is also an author of two recently published books “The Allergy Epidemic: A mystery of modern life” and “The Calling: A true story of faith, hope and love” based on her grandmother’s pioneering medical footsteps.

Professor Prescott has been an ASCIA member since 1996 and is a regular presenter and chair at ASCIA Annual Scientific Meetings. She is actively involved in the ASCIA Paediatric committee, contributing to the development of several ASCIA educational resources, particularly in the areas of allergy prevention and infant feeding advice. She is also a member of the World Allergy Organisation (WAO) Board of Directors and regularly presents at International conferences.

At ASCIA 2013 Professor Prescott will be presenting as follows:

1. **Basten Oration: Allergy and the NCD Pandemic; the Canary in the Coal Mine** on Wednesday 11 September, 09.00-09.30

Other Invited Speakers

- Prof Katie Allen VIC
- Dr Anthony Bosco WA
- Dr Jack Bourke WA
- Prof Simon Brown WA
- Dr Andrew Currie WA
- Dr Theo de Matmanche NSW
- Ms Rachael Dunn WA
- Ms Jo Elliot WA
- Prof Martyn French WA
- A/Prof David Fulcher NSW
- Dr Eliska Furlong WA
- A/Prof Peter Hollingsworth WA
- Dr Tiffany Hughes SA
- Ms Monica Kemp WA
- A/Prof Allan Kermode WA
- A/Prof Richard Loh WA
- Adj A/Prof Michaela Lucas WA
- Dr David Martino VIC
- Dr Benjamin McGettigan WA, NZ
- Dr Andrew McLean-Tooke WA
- Ms Vicki McWilliam VIC
- Dr Sam Mehr NSW
- Dr Raymond Mullins ACT
- Ms Merryn Netting SA
- Dr David Nolan WA
- A/Prof Debra Palmer WA
- Prof Elizabeth Phillips WA
- Ms Anna Richards NZ
- A/Prof Sean Riminton NSW
- Ms Gerhard Saueracker WA
- Dr William Smith SA
- Dr Shelley Stone WA
- A/Prof Mimi Tang VIC
- Dr Adelaide Withers WA
- A/Prof Campbell Witt WA
- Dr Melanie Wong NSW

Chairs

- Dr John Bandouvakis WA
- Dr Sara Barnes VIC
- Ms Kathy Beck QLD
- Dr Shannon Brothers NZ
- Ms Paula Brown QLD
- Dr Anna Brusch WA
- Dr Christine Bundell WA
- Ms Pamela Burton NSW
- Prof Dianne Campbell NSW
- Ms Barbara Dennison NSW
- Ms Rachael Dunn WA
- Prof Martyn French WA
- Mr Mark Goulding WA
- A/Prof Bob Heddle SA
- Dr Meilyn Hew WA
- A/Prof Peter Hollingsworth WA
- Dr Tiffany Hughes SA
- Dr Miriam Hurst NZ
- Dr Preeti Joshi NSW
- Prof Connie Katelaris NSW
- A/Prof Allan Kermode WA
- A/Prof Richard Loh WA
- Ms Evania Marlow WA
- Dr Jeremy McComish VIC
- Dr Andrew McLean-Tooke WA
- Ms Valerie Noble WA
- Dr Richard Nolan WA
- Ms Vicki O’Brien WA
- Dr Michael O’Sullivan WA
- Ms Sacha Palmer SA
- Dr Jane Peake QLD
- Prof Susan Prescott WA
- Dr Robert Puy VIC
- Dr Patrick Quinn SA
- Dr Peter Richmond WA
- A/Prof Sean Riminton NSW
- Ms Ingrid Roche WA
- Prof Pete Smith QLD
- Dr William Smith SA
- Dr Colin Somerville WA
- Dr Melanie Wong NSW
- Dr Celia Zubrinich VIC
Abstracts

Poster and Clinical Grand Rounds abstracts listed in this book have been published online in the Internal Medicine Journal (IMJ) in September 2013. Refer to the ASCIA website: www.allergy.org.au/health-professionals/meetings/asclia-annual-scientific-meetings/published-abstracts-asclia

Accommodation

Contact details for the main Perth hotels booked by ASCIA 2013 delegates are as follows:

Adina Apartment Hotel
Address: 33 Mounts Bay Road, Perth (next to the Perth Convention and Exhibition Centre)
Website: www.adinahotels.com.au/adina-apartmenthotel-perth/hotel
Email: perth@adinahotels.com.au
Phone: 08 9217 8000

Rydges Hotel Perth
Address: 815 Hay Street, Perth (corner King Street) - approximately 10 minutes walk from PCEC
Website: www.rydges.com/accommodation/western-australia/perth-cbd/
Email: reservations_perth@rydges.com
Phone: 08 9263 1800

Mounts Bay Waters Apartments
Address: 112 Mounts Bay Road, Perth - approximately 10 minutes walk from PCEC
Website: www.mounts-bay.com.au/
Email: perth@waldorf.com.au
Phone: 1800 241 343

For information about other Perth hotels visit: www.westernaustralia.com/au/Search/Pages/Search.aspx?r=1&pretty=experience_perth/Accommodation

Attendance Certificates

Certificates of attendance are included in the registration envelope, together with a receipt for the registration payment.

Attractions

- Kings Park and Botanic Garden, one of the largest and most scenic inner city parks in the world and a short (but steep) walk from the Perth Convention and Exhibition Centre: www.bgpa.wa.gov.au/kingspark
- Riverside walking and cycling track from Perth to Crawley, which passes by the historical Old Swan Brewery Bar and Restaurant. www.theoldbrewery.com.au/
- Cottesloe Beach, about 30 minutes drive from Perth and you can watch a spectacular sunset over the Indian Ocean: www.westernaustralia.com/en/Things_to_See_and_Do/Sun_Surf_and_Sea_Life/Pages/Perth_Beaches.aspx
- Fremantle is a further 15 minutes drive from Cottesloe, and is a historical port city with an excellent waterfront Maritime Museum and a range of other historical and cultural attractions. www.fremantlewesternaustralia.com/
- Rottnest Island – this can be visited in a day by catching a ferry from Perth or Fremantle: www.rottnestisland.com/
- Swan Valley is famous for its food and wine and is located just 25 minutes from the Perth city centre - wine cruises on the Swan river are a popular way to explore this region: www.swanvalley.com.au
- Margaret River region is famous for its wines and beaches, and is a 3-4 hour drive south from Perth: www.margaretriver.com/regions/
- Western Australian wildflowers are renowned as being one of the most spectacular wildflower displays in the world from June to November: www.westernaustralia.com/en/Things_to_See_and_Do/Forest_and_Flowers/WAWildflowers/Pages/WAWildflowers.aspx
- For general information about Western Australia visit www.westernaustralia.com

Awards and Travel Scholarships

- Clinical Grand Rounds Prize/s for advanced trainees ($2,500) supported by Stallergenes
- Food Allergy Poster Prize ($1,000) supported by Nestlé Nutrition
- Immunopathology Poster Prize ($1,000) supported by Abacus ALS
- NAC Asthma Poster Prize ($1,000) supported by the National Asthma Council (NAC)
- Nurses Poster Prize/s ($2,500) supported by Stallergenes
- Paul Clarke Allergy Poster Prize ($1,000) supported by ASCIA
- PID Poster or Presentation Prize ($1,000) supported by CSL Behring

A total of twenty ASCIA 2013 Travel Scholarships for Advanced Trainees of $500 each have been awarded and these are supported by educational grants of $2,500 each from Abacus-ALS, ASCIA, CSL Behring and Stallergenes.
**Breakfast Sessions**
Breakfast sessions are included in the ASCIA 2013 ASM registration fee. For catering purposes delegates must RSVP when they register for ASCIA 2013.

**Disclaimers**
In the event of industrial disruption or a natural disaster the meeting organisers cannot be held responsible for any losses incurred by delegates. The program is correct at the time of printing; however the organisers reserve the right to alter the program if necessary.

**Dress Code**
The dress code is smart casual throughout the meeting and cocktail for the Gala Dinner.

**Exhibition**
We encourage delegates to visit the ASCIA 2013 exhibition stands throughout the meeting which is located in the Perth Convention and Exhibition Centre in Bellevue Ballroom 1 from Wednesday 11th to Friday 13th September and in the Foyer adjacent to Riverview Room 4 on Saturday 14th September 2013. Lunches and tea breaks will be served in these exhibition areas.

**Secretariat**
**Registration and Abstract submission**
ICMS Australasia Pty Ltd
GPO Box 3270 Sydney
NSW 2001
Phone: 02 9254 5000
Fax: 02 9251 3552
Email: registration@ascia2013.com.au
Website: www.ascia2013.com.au

**Sponsorship, Exhibition and Program Inquiries**
ASCIA Executive Officer
PO Box 450 Balgowlah
NSW Australia 2093
Ph: 0425 216 402
Fax: 02 9907 9773
Email: education@allergy.org.au
Website: www.ascia2013.com.au

**Smoke Free Policy**
It is the policy that the ASCIA 2013 meeting area of the venue and all related social functions are smoke-free.

**Social Program**
**ASCIA 2013 Welcome Function**
Wednesday 11 September, 18.00 to 19.00
Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer

**ASCIA 2013 Gala Dinner**
Thursday 12 September, 18.30 to 22.30
State Reception Centre, Frasers Restaurant, Kings Park

**ASCIA 2013 Closing Function / Wine and Cheese including CGR and Poster awards**
Friday 13 September, 17.00-18.00
Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer

**Concurrent sponsored dinners**
Friday 13 September, 19.00, including:
Trainee and Consultants Dinner supported by CSL Behring, Parmelia Hilton Hotel Perth
Nurses Dinner supported by Stallergenes, Parmelia Hilton Hotel Perth

**Wine and Cheese: ASCIA 2013 Immunopathology Update; ASCIA 2013 Allergy and Immunology Update**
Saturday 14 September, 17.00-18.00
Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4

**Special Requirements**
Please provide details of any special diet, special needs or disability assistance required when you register.

**Travel**
Perth is regularly accessed by flights from capital cities in Australia and New Zealand. Perth Airport is around 30 minutes drive to the Perth City Centre, where the Perth Convention and Exhibition Centre is located. Transport options to and from the Airport include taxis or airport buses.
Which of your patients is at risk of anaphylaxis?
Help them be prepared with 2x EpiPen® Adrenaline Auto-Injectors

My tongue feels strange when I eat eggs.

PBS Information: Authority Required. Refer to PBS Schedule for full authority information.

MINIMUM PRODUCT INFORMATION EpiPen® Adrenaline Auto-Injector 0.3 mg / 0.3 mL. EpiPen® Jr. Adrenaline Auto-injector 0.15 mg / 0.3 mL. The following are not a complete listing: Indication: For the emergency treatment of anaphylaxis (acute severe allergic reaction) due to insect stings or bites, foods, drugs or other allergens. Contraindications: Contraindications are relative; as this product is intended for use in life-threatening emergencies. Certain arrhythmias, cerebral arteriosclerosis, vasopressor drug contraindication, shock (except anaphylactic shock), certain types of general anesthesia. Precautions: Sulfite allergy, intravenous administration, ventricular fibrillation, premonitory rhythm, tachycardia, myocardial infarction, cardiovascular disease, organic heart disease, cardiac dilation, cerebral arteriosclerosis, proctocolitis hypotrophy, elderly, individuals with diabetes, hypertension, narrow angle glaucoma, hyperthyroidism, organic brain damage, psychoneurosis, phaeochromocytoma-induced circulatory collapse, Parkinsonism. Avoid injection into hands, feet, ears, nose, buttocks, genitalia. Use in Pregnancy: Pregnancy Category A. Excercised in breast milk. Use with caution when maternal blood pressure is in excess of 130/80. Interactions: CNS medicines, alpha and beta adrenergic blockers, some general anaesthetics, hypoglycaemic agents. Adverse Effects: Anxiety, restlessness, tachycardia, respiratory difficulty, tremor, weakness, dizziness, headache, dyspnoea, cold extremities, pallor, sweating, nausea, vomiting, sleeplessness, hallucinations, flushing of face and skin. Psychomotor agitation, disorientation, impaired memory, potentially fatal ventricular arrhythmias, severe hypertension which may lead to cerebral haemorrhage and pulmonary oedema. Angina may occur in patients with CAD. Dosage: Single intramuscular injection into anterolateral aspect of thigh, repeat as directed if symptoms recur or have not subsided. Adults > 30kg: EpiPen® Auto-Injector (0.3 mg adrenaline); Children 15-30kg: EpiPen® Jr. Auto-Injector (0.15 mg adrenaline). The prescribing physician may choose to prescribe more or less than this amount; please refer to relevant guidelines.


Forward Thinking Pharmacy
NESTLÉ | OFFERING THE COMPLETE ALLERGY SOLUTION
FROM RISK REDUCTION TO MANAGEMENT IN FORMULA FED INFANTS

NAN® H.A. 1 Gold
The only clinically proven H.A. starter infant formula shown to reduce allergy risk by up to 50% in high-risk formula fed infants.†,‡

† Compared to intact cows’ milk formula

ALFARE®
Australian & International Guidelines recommend an extensively hydrolysed formula such as ALFARE® as the 1st choice in treating cow’s milk allergy in infants under 6 months of age.³,⁴,⁵

ALFAMINO® COMING SOON*
Introducing the latest development in hypoallergenic elemental formulas for the nutritional management of severe & complicated cases of Cow’s Milk Protein Allergy & Food Intolerance. Based on 100% free amino acids.

Important Notice: Breast milk is best for babies and provides ideal nutrition. Good maternal nutrition is important for preparation and maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing a decision not to breastfeed is difficult. Professional advice should be followed on infant feeding. Infant formula should be prepared and used exactly as directed or it could pose a health hazard. The preparation requirements and cost of providing infant formula until 12 months of age should be considered before making a decision to formula feed.


THIS MATERIAL IS FOR HEALTHCARE PROFESSIONALS ONLY
Nutricia leads the way in providing a comprehensive portfolio of products for Advanced Allergy Management in infants. Our products are scientifically researched for protection from and management of cows’ milk protein allergy, and can help you make a difference to the lives of the infants, children and mothers you care for along their allergy journey.

We look forward to seeing you at our Nutricia Advanced Allergy Management stand at ASCIA 2013.

**ALLERGY PROTECTION**

**HEALTHY INFANTS**
(Up to 20% risk of allergy)

**FAMILY HISTORY OF ALLERGY**

**ALLERGY MANAGEMENT**

**COWS’ MILK PROTEIN ALLERGY**

- **MILD TO MODERATE**
  (Effective management in up to 9 out of 10 cases²³)

- **MODERATE TO SEVERE**
  (Including eosinophilic oesophagitis, anaphylaxis and failure to thrive)

![Aptamil Gold+](image)
![Aptamil Gold+ HA](image)
![Aptamil Gold+ AllerPro](image)
![Neocate Amino Acid](image)

* For detailed guidelines on the management of cows’ milk protein allergy, please refer to Kemp AS et al. MJA 2008; 188(21): 109–112.

---

**REFERENCES**

WE’RE FIGHTING THE SAME FIGHT

I HAVE A SEVERE RESPIRATORY ALLERGY

I’M AN IMMUNOTHERAPY RESEARCHER

The biopharmaceutical company Stallergenes has been driving research and collaboration with the medical community for 50 years now and is at the forefront of allergen immunotherapy.

INNOVATION AT HAND PATIENTS AT HEART
WHO IS AIFA?

The Allergy and Immunology Foundation of Australia (AIFA) is an initiative of the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australasia. AIFA is dedicated to funding education and research into disorders of the human immune system in Australia and New Zealand.

These disorders encompass **allergy**, including asthma, and other **immune diseases** such as primary immunodeficiency and autoimmune diseases.

WHY DO ALLERGY AND IMMUNE DISEASES MATTER?

Allergy and other immune diseases are amongst the fastest growing chronic and complex health conditions affecting children and adults in Australasia.

Allergic disease, and in particular food allergy, is rapidly increasing in young children.

Severe allergic reactions (anaphylaxis) and primary immunodeficiency diseases are potentially life threatening and cause significant impairment in day to day functioning.

WHAT NEEDS TO BE DONE?

More **research** is urgently needed into:

- Potential new treatments and cures for allergy, primary immunodeficiency and autoimmune diseases.
- Understanding why allergy and immune diseases are increasing so rapidly.
- Preventing allergy from occurring in the first place.
- Genetic testing and newborn screening for primary immunodeficiency.

High quality and far reaching **education** programs are urgently required to educate:

- Health professionals about early detection of allergy and immune diseases.
- The community about allergy and immune diseases.
HOW CAN YOU HELP?

Every dollar counts.

By donating to AIFA you can help fund high quality education or research projects, selected by an expert panel, that have the greatest potential to help make a difference to 1 in 4 Australians and New Zealanders with allergy or other immune diseases.

Donations to AIFA can be made online at www.allergyimmunology.org.au or by cheque or EFT.

Donations of $100 or more will be listed on the AIFA website (subject to donor permission) and donors of $100,000 or more will be listed as founding sponsors of AIFA.

FAST FACTS

1. Allergy and Immune diseases (Immunodeficiency and autoimmune diseases) are among the fastest growing chronic conditions in Australasia.
2. Almost 20% of Australians and New Zealanders have an allergic disease and this prevalence is increasing.
3. Hospital admissions for life threatening anaphylaxis (severe allergic reactions) have increased 4 fold in the last 20 years.
4. Food-Induced anaphylaxis has doubled in the last 10 years and 10% of infants now have an immediate food allergy.
5. Immunodeficiency diseases are serious, potentially life threatening conditions that are increasing in number and complexity.
6. Delay in diagnosis of immunodeficiency disease leads to poor health outcomes and premature death.
7. Autoimmune diseases affect 5% of Australians and New Zealanders and are more common than cancer or heart disease.
8. There are over 100 different autoimmune diseases that affect Australians and New Zealanders, and lead to significant disability.
9. There is a lack of public awareness about the impact and appropriate management of allergy and immune diseases.
10. Access to care is difficult, even in metropolitan areas, due to the high number of patients and low number of appropriately trained health care professionals, resulting in long waiting times to see a specialist.

Although this information is based on Australian data, it is expected that similar prevalence figures apply in New Zealand.
### Clinical Grand Rounds: Program

**Wednesday 11 September 2013, 16.00-18.00**  
**Perth Convention and Exhibition Centre, Bellevue Ballroom 2**

**Chairs:** Prof Dominic Mallon, Prof Pete Smith

Each presentation has been allocated 8 minutes, comprising 4 minutes for a Powerpoint presentation (8 slides maximum) followed by 4 minutes for questions and discussion.

<table>
<thead>
<tr>
<th>CGR</th>
<th>16:00-16:08</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGR 1</td>
<td>16.00-16.08</td>
<td>Russell Barker</td>
<td>AN AETIOLOGY FOR IGG4 RELATED DISEASE?</td>
</tr>
<tr>
<td>CGR 2</td>
<td>16.08-16.16</td>
<td>Dinusha Chandratilleke</td>
<td>A CULPRIT ANTIBODY SEIZES THE DAY</td>
</tr>
<tr>
<td>CGR 3</td>
<td>16.16-16.24</td>
<td>Jie Shen (Jason) Fok</td>
<td>A FATAL SWEET EXPERIENCE</td>
</tr>
<tr>
<td>CGR 4</td>
<td>16.24-16.32</td>
<td>Lara Ford</td>
<td>SWEET SYNDROME IN A 16-YEAR-OLD GIRL</td>
</tr>
<tr>
<td>CGR 5</td>
<td>16.32-16.40</td>
<td>Katie Frith</td>
<td>ONE IN A MILLION</td>
</tr>
<tr>
<td>CGR 6</td>
<td>16.40-16.48</td>
<td>Melanie Hettiarachchi</td>
<td>CLONAL PROLIFERATION OF T CELLS IN A YOUNG WOMAN WITH THE HYPEREOSINOPHILIC SYNDROME</td>
</tr>
<tr>
<td>CGR 7</td>
<td>16.48-16.56</td>
<td>Stephanie Hogarth</td>
<td>TRICHO-HEPATO-ENTERIC SYNDROME - THE FIRST CASE DESCRIBED IN AUSTRALIA</td>
</tr>
<tr>
<td>CGR 8</td>
<td>16.56-17.04</td>
<td>Jovanka King</td>
<td>USE OF ADJUNCTIVE SYSTEMIC CIDOFOVIR THERAPY IN A CHILD WITH SEVERE RECURRENT RESPIRATORY PAPILLOMATOSIS</td>
</tr>
<tr>
<td>CGR 9</td>
<td>17.04-17.12</td>
<td>Paul Mansfield</td>
<td>NOT SO HELPFUL T LYMPHOCYTES</td>
</tr>
<tr>
<td>CGR 10</td>
<td>17.12-17.20</td>
<td>Claire Nickolls</td>
<td>A CASE OF NEONATAL LIVER FAILURE: IRONING OUT THE DIAGNOSIS</td>
</tr>
<tr>
<td>CGR 11</td>
<td>17.20-17.28</td>
<td>Lawrence Ong</td>
<td>SECONDARY HYPOGAMMAGLOBULINAEMIA FOLLOWING LONG TERM ANTIEPILEPTIC USE: AN UNCOMMON CAUSE OF SECONDARY IMMUNODEFICIENCY</td>
</tr>
<tr>
<td>CGR 12</td>
<td>17.28-17.36</td>
<td>Alberto Pinzon-Charry</td>
<td>INTRALESIONAL STEROIDS FOR THE TREATMENT OF CUTANEOUS GRANULOMAS IN ATAXIA TELANGIECTASIA</td>
</tr>
<tr>
<td>CGR 13</td>
<td>17.36-17.44</td>
<td>Jody Tansy</td>
<td>RITUXIMAB EFFECTIVE FOR LYMPHOCYTIC INTERSTITIAL PNEUMONITIS ASSOCIATED WITH SJOGREN'S SYNDROME: A CASE REPORT</td>
</tr>
<tr>
<td>CGR 14</td>
<td>17.44-17.52</td>
<td>Nicolas Utriola</td>
<td>A BRAF NEW WORLD</td>
</tr>
<tr>
<td>CGR 15</td>
<td>17.52-18.00</td>
<td>Andrew Whyte</td>
<td>LIMB-GIRDLE MUSCULAR DYSTROPHY: AN IMMUNOLOGICAL CONDITION?</td>
</tr>
</tbody>
</table>
Poster Abstracts: Index 2013

Note:
ASM = Annual Scientific Meeting 11-13 September 2013
IPU = Immunopathology Update 14 September
AIU = Allergy and Immunology Update 14 September

P1 (ASM) Jodie Abramovitch IGE REACTIVITY OF BLUE SWIMMER CRAB (PORTUNUS PELAGICUS) TROPOMYOSIN, FOR P 1, AND OTHER ALLERGENS; CROSS-REACTIVITY WITH BLACK TIGER PRAWN AND EFFECTS OF HEATING

P2 (ASM, IPU) Nayyar Ahmed DISCOVERING THE EFFECTS OF OMEGA-3 FATTY ACIDS ON ALLERGY USING A HEK-BLUE CELL LINE

P3 (ASM, IPU) Nayyar Ahmed IDENTIFICATION AND CHARACTERIZATION OF A NOVEL CYTOKINE IL-13 ANTAGONIST FOR ALLERGY TREATMENT

P4 (ASM) Janet Anderson UPDATE ON THE UTILITY OF CHLORHEXIDINE SPECIFIC IGE TESTING IN THE INVESTIGATION OF PERIOPERATIVE ALLERGY

P5 (ASM) Ulus Atasoy RNA-BINDING PROTEIN HUR COORDINATELY REGULATES GATA-3, CD4+ TH2 AND TH17 CYTOKINE GENE EXPRESSION IN DOSE-DEPENDENT MANNER

P6 (ASM) Sara Barnes EVOLVING PRACTICE: X LINKED AGAMMAGLOBULINEMIA AND LUNG TRANSPLANTATION

P7 (ASM) Sara Barnes THE CHILD WITH A FOOD ALLERGY: CHALLENGES TO OUR FOOD SERVICE SYSTEM

P8 (ASM, AIU) Melanie Batchelor ANAPHYLAXIS DISCHARGE MANAGEMENT: IDENTIFYING GAPS AND REDUCING THE RISK

P9 (ASM, AIU) Melanie Batchelor FACTORS THAT INFLUENCE ADRENALINE AUTOINJECTOR NON-USAGE

P10 (ASM) Andrew Broadfoot EVALUATION OF CEFACLOR ELISA TESTING

P11 (ASM, IPU) Shannon Brothers RETROSPECTIVE REVIEW OF VARELISA ANTI-GLOMERULAR BASEMENT MEMBRANE ASSAY PERFORMANCE

P12 (ASM, IPU) Christine Bundell LOW LEVEL AUTOANTIBODIES ARE COMMON IN A GENERAL AUSTRALIAN POPULATION

P13 (ASM, IPU) Christine Bundell ANTINUCLEAR ANTIBODY TESTING IN A WESTERN AUSTRALIAN IMMUNOPATHOLOGY LABORATORY

P14 (ASM, AIU) Pamela Burton COMPARISON OF THREE SKIN PRICK TEST METHODS IN A PAEDIATRIC POPULATION

P15 (ASM, AIU) Pamela Burton CONSTRUCTION OF A GRASS POLLEN CALENDAR FOR THREE REGIONS IN GREATER SYDNEY

P16 (ASM, AIU) Pamela Burton INVESTIGATIONS AND FOLLOW UP OF PATIENTS WHO PRESENTED WITH LOCAL ANAESTHETIC REACTIONS

P17 (ASM, AIU) Pamela Burton NURSING STAFF KNOWLEDGE OF LATEX ALLERGY IN A TEACHING HOSPITAL

P18 (ASM) Dianne Campbell OUTCOME OF ORAL FOOD CHALLENGES TO BAKED MILK IN MILK ALLERGIC CHILDREN

P19 (ASM) Gary Chew GRANULOMATOUS DISEASE IN PRIMARY ANTIBODY DEFICIENCY: ANALYSIS FROM THE AUSTRALIAN NEW ZEALAND ANTIBODY DEFICIENCY ALLELE STUDY (ANZADA)

P20 (ASM) Miriam Codarini MEETING ALLERGY TRAINING NEEDS FOR PHYSICIANS WITH AN INNOVATIVE ONLINE COURSE

P21 (ASM) Janet Davies INCOMPLETE IgE CROSS-REACTIVITY BETWEEN POLLEN ALLERGEN FROM SUBTROPICAL AND TEMPERATE GRASSES IN PATIENTS FROM THE SUBTROPICS
<table>
<thead>
<tr>
<th>Page</th>
<th>Authors</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P22</td>
<td>Janet Davies</td>
<td>REGIONAL AND SEASONAL VARIATION IN AIRBORNE GRASS POLLEN LEVELS BETWEEN CITIES OF AUSTRALIA AND NEW ZEALAND</td>
</tr>
<tr>
<td>P23</td>
<td>Maneka Deo</td>
<td>CANDLENUT ALLERGY IN NEW ZEALAND</td>
</tr>
<tr>
<td>P24</td>
<td>Suran Fernando</td>
<td>AN INTRIGUING CASE OF AMINE INTOLERANCE FOLLOWING A GENERALISED CUTANEOUS REACTION TO HONEY BEE VENOM</td>
</tr>
<tr>
<td>P25</td>
<td>Jie Shen Fok</td>
<td>USE OF ICATIBANT IN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR-ASSOCIATED ANGIOEDEMA: OUR EXPERIENCE IN AUSTRALIA</td>
</tr>
<tr>
<td>P26</td>
<td>Alexander Headley</td>
<td>INVESTIGATING BASOPHIL NUMBER AND FUNCTION</td>
</tr>
<tr>
<td>P27</td>
<td>Peter Hsu</td>
<td>A PAEDIATRIC CASE SERIES OF SYSTEMIC CAPILLARY LEAK SYNDROME</td>
</tr>
<tr>
<td>P28</td>
<td>Miriam Hurst</td>
<td>OMEGA 5 GLIADIN POSITIVITY: NEW ZEALAND EXPERIENCE</td>
</tr>
<tr>
<td>P29</td>
<td>Sandip Kamath</td>
<td>DETECTION AND QUANTIFICATION OF THE AEROSOLIZED FOOD ALLERGEN TROPOMYOSIN - THE MAJOR SHELLFISH ALLERGEN</td>
</tr>
<tr>
<td>P30</td>
<td>Jovanka King</td>
<td>IGE-MEDIATED Povidone Allergy Presenting with Anaphylaxis: A Cause of Multiple Drug Allergy</td>
</tr>
<tr>
<td>P31</td>
<td>Elizabeth Klinken</td>
<td>MUCOSAL ASSOCIATED INVARIANT T (MAIT) CELL NUMBERS ARE REDUCED IN THE PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS PATIENTS</td>
</tr>
<tr>
<td>P32</td>
<td>Jamma Li</td>
<td>AQUAPORIN-4 TRANSFECTED CELLS IN THE DIAGNOSIS OF NEUROMYELITIS OPTICA</td>
</tr>
<tr>
<td>P33</td>
<td>Andreas Lopata</td>
<td>IN-VITRO ATOPY TESTING USING A NOVEL MODIFIED ELISA SYSTEM - THE FastCheck POC20</td>
</tr>
<tr>
<td>P34</td>
<td>Sam Mehr</td>
<td>THE FIRST 12 MONTHS OF FPIES SURVEILLANCE IN AUSTRALIA</td>
</tr>
<tr>
<td>P35</td>
<td>Fiona Moghaddas</td>
<td>AN ATYPICAL CLINICAL COURSE OF ISCHAEMIC BOWEL IN A PATIENT WITH HEREDITARY ANGIOEDEMA TREATED INITIALLY WITH ICATIBANT</td>
</tr>
<tr>
<td>P36</td>
<td>Fiona Moghaddas</td>
<td>OMAIZUMAB USE IN THE PREVENTION OF DELAYED REACTIONS POST VENOM IMMUNOTHERAPY: TWO CASES</td>
</tr>
<tr>
<td>P37</td>
<td>Philippe Moingeon</td>
<td>SCIENTIFIC RATIONALE SUPPORTING THE USE OF BOTH DERMATOPHAGOIDES PTERONYSSINUS AND D. FARINAE EXTRACTS FOR SPECIFIC IMMUNOTHERAPY</td>
</tr>
<tr>
<td>P38</td>
<td>Mary Moussa</td>
<td>SPRING: SYDNEY PROFESSIONAL IMMUNOLOGY NURSES GROUP</td>
</tr>
<tr>
<td>P39</td>
<td>Mahila Namasivayam</td>
<td>QUANTIFICATION OF HUMAN CYTOMEGALOVIRUS-SPECIFIC T-CELL RESPONSES IN PAEDIATRIC PATIENTS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANTATION</td>
</tr>
<tr>
<td>P40</td>
<td>Katherine Nicholls</td>
<td>COMPARATIVE ANALYSIS OF ENZYME LINKED IMMUNOSORBENT AND MULTIPLEX BEAD ARRAY ASSAYS FOR DETECTION OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES WITH SPECIFICITY FOR MYELOPEROXIDASE AND PROTEINASE 3</td>
</tr>
<tr>
<td>P41</td>
<td>Emmanuel Nony</td>
<td>MASS SPECTROMETRIC ANALYSIS OF MAJOR ALLERGEN STABILITY WITHIN MIXTURES OF ALLERGENIC EXTRACTS INTENDED FOR IMMUNOTHERAPY</td>
</tr>
<tr>
<td>P42</td>
<td>Adeloisa Pajaro</td>
<td>RECURRENT POSTOPERATIVE PERICARDITIS IN A 39 YEAR OLD WOMAN TREATED WITH IMMUNOSUPPRESSIVE THERAPY AND INTERLEUKIN-1B RECEPTOR ANTAGONIST (ANAKINRA)</td>
</tr>
<tr>
<td>P43</td>
<td>Alberto Pinzon-Charry</td>
<td>ANTIAMALARIAL TREATMENT RESTORES DENDRITIC CELL FUNCTION IN PATIENTS WITH MALARIA: IMPLICATIONS FOR VACCINATION</td>
</tr>
<tr>
<td>P44</td>
<td>Kerri Prain</td>
<td>LABORATORY TESTING FOR ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS - THE HSSA-PATHOLOGY QUEENSLAND EXPERIENCE</td>
</tr>
<tr>
<td>P45</td>
<td>Kahn Preece</td>
<td>BACK TO BASICS</td>
</tr>
<tr>
<td>ID</td>
<td>(ASM, IPU)</td>
<td>Name</td>
</tr>
<tr>
<td>-----</td>
<td>------------</td>
<td>---------------</td>
</tr>
<tr>
<td>P46</td>
<td>(ASM, IPU)</td>
<td>Alex Quach</td>
</tr>
<tr>
<td>P47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P48</td>
<td>(ASM)</td>
<td>Katrina Randall</td>
</tr>
<tr>
<td>P49</td>
<td>(AIU)</td>
<td>Susan Rochford</td>
</tr>
<tr>
<td>P50</td>
<td>(ASM, AIU)</td>
<td>Sandra Salter</td>
</tr>
<tr>
<td>P51</td>
<td>(ASM)</td>
<td>Michael Sharp</td>
</tr>
<tr>
<td>P52</td>
<td>(AIU)</td>
<td>Farrukh Sheikh</td>
</tr>
<tr>
<td>P53</td>
<td>(ASM)</td>
<td>Charlotte Slade</td>
</tr>
<tr>
<td>P54</td>
<td>(ASM)</td>
<td>Carling Southall</td>
</tr>
<tr>
<td>P55</td>
<td>(ASM)</td>
<td>Ju Ann Tan</td>
</tr>
<tr>
<td>P56</td>
<td>(ASM)</td>
<td>Ju Ann Tan</td>
</tr>
<tr>
<td>P58</td>
<td>(ASM)</td>
<td>Grace Thompson</td>
</tr>
<tr>
<td>P59</td>
<td>(ASM)</td>
<td>Tilenka Thynne</td>
</tr>
<tr>
<td>P60</td>
<td>(ASM)</td>
<td>Euan Tovey</td>
</tr>
<tr>
<td>P61</td>
<td>(ASM)</td>
<td>Sheryl Van Nunen</td>
</tr>
<tr>
<td>P62</td>
<td>(ASM)</td>
<td>Sheryl Van Nunen</td>
</tr>
<tr>
<td>P63</td>
<td>(ASM)</td>
<td>Sheryl Van Nunen</td>
</tr>
<tr>
<td>P64</td>
<td>(ASM)</td>
<td>Nirupama Varese</td>
</tr>
<tr>
<td>P65</td>
<td>(ASM, AIU)</td>
<td>Carol Whitehead</td>
</tr>
</tbody>
</table>
ASCIA 2013 Exhibition Floorplan

Please note:

- The Bellevue Ballroom 1 Pre-Function Lobby is the main entrance and the ASCIA 2013 registration desk will be located in this area.
- ASCIA 2013 presentations from Tuesday to Friday will be in Bellevue Ballroom 2.
- Catering and seating will be located in the ASCIA 2013 exhibition area.
- Posters will be displayed in the adjacent Bellevue Ballroom 2 Pre-Function foyer.
- Table top exhibition displays for the Saturday meetings are located in the foyer outside Riverview Room 4 and Meeting rooms 1-3 on level 2 of the Perth Convention and Exhibition Centre. These are not allocated stand numbers.
- The content of ASCIA 2013 is not influenced by its sponsors or exhibitors.
<table>
<thead>
<tr>
<th>Stand No.</th>
<th>Exhibitor</th>
<th>Wed-Fri</th>
<th>Sat</th>
</tr>
</thead>
<tbody>
<tr>
<td>23,24</td>
<td>Abacus ALS</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>Allergend</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>Allergy &amp; Anaphylaxis Australia</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>Allergy New Zealand</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>39,40</td>
<td>Alphapharm</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>Asthma Australia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>AusEE</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>36</td>
<td>AMSL/NZMS</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>20,21</td>
<td>Baxter</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>Bio-Strategy</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1,2</td>
<td>CSL Behring</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Diagnostic Solutions</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>29</td>
<td>Ego Pharmaceuticals</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ESL Biosciences</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>GSK</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>HAE Australasia</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>IDFA</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>IDFNZ</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>In Vitro Technologies</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>33</td>
<td>Link</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>31</td>
<td>Meda</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>MedicAlert Foundation</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>9,10</td>
<td>MSD</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Neilmed</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>27,28</td>
<td>Nestlé Nutrition</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>37,38</td>
<td>Novartis</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Nutricia Baby</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Nutricia Advanced Medical</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Octapharma</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>34,35</td>
<td>Shire Australia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>25,26</td>
<td>Stallergenes</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>Takeda</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>TAMS</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>32</td>
<td>ViroPharma</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
Abacus ALS will showcase a number of new advances in allergy, asthma and autoimmunity. Kerstin Wall (Scientific Advisor, Thermo Fisher Scientific) will be on our booth to discuss the new and updated allergen components including those to wheat, walnut, cashew, hazelnut, grass and birch.

Molecular Allergology can help with risk assessment of the allergy, explain symptoms due to cross-reactivity and help in identifying patients suitable for SIT treatment while supporting the doctor in patient management.

The gastrointestinal disease test menu on the Phadia® platforms has expanded to include EliA ASCA in addition to the fully automated Calprotectin stool test for diagnosing sufferers of IBD. These new tests complement our existing range of EliA assays including our leading assays for diagnosing coeliac disease (Celikey tTG and DGP).

Abacus ALS will provide visitors to our booth a complimentary copy of the most up-to-date allergy and autoimmunity resources on a USB stick.

Abbott Nutrition, a division of Abbott Australasia is committed to advancing patient care by developing innovative solutions in nutritional products. Our leading-edge science is behind some of the world’s most trusted names in medical nutrition, including EleCare®, which is a nutritionally complete amino acid based formula with 1/3 of fat as Medium Chain Triglycerides (MCTs), to aid fat absorption. This product has been specially formulated for infants and children who have multiple food allergies, including cow’s milk protein allergy. In addition, EleCare Unflavoured and EleCare Vanilla are also indicated for the treatment of Eosinophilic Oesophagitis. EleCare® is PBS listed and is available in three variants, EleCare Unflavoured, EleCare Unflavoured with LCP and EleCare Vanilla.

AllergEnd Plus is the Ultimate dust mite protective bedding. Made in Melbourne, our AllergEnd Plus bedding range has established us as market leaders. Our fully zippered pillow, mattress and quilt encasings act as a complete barrier to dust mites and their associated allergens. It is a breakthrough in dust mite protection. The AllergEnd Plus fabric is Oeko-Tex Standard 100 certified chemical free cotton that is breathable and luxuriously comfortable to sleep on.

AllergEnd Plus can be purchased online at www.allergend.com.au, via phone on Free Call 1800 656 484 or in person direct from our factory at 132a Cotham Road, Kew Victoria 3101.

Allergy & Anaphylaxis Australia (A&AA) is a national, non-profit community support organisation established in 1993 to support and assist those affected by allergy and anaphylaxis.

Allergy & Anaphylaxis Australia is dedicated to assisting individuals and their carers in the management of allergic disease including the risk of anaphylaxis. Our aim is to improve the quality of life of those affected by allergy whilst minimising risk to their health and well-being. The organisation advocates for people living with allergies when communicating with government, health and teaching professionals, food industry and the broader community.

Allergy & Anaphylaxis Australia strives to raise awareness of allergy in the Australian community and provides evidence-based information, resources and services to support those with allergy and those who live with the risk of anaphylaxis.

For more information on allergy and anaphylaxis see our website or call 1300 728 000.
support through a national volunteer network to families with children with food allergy. Our quarterly magazine, Allergy Today, is distributed to over 5,000 health professionals. We also represent the interests of the allergic population through submissions and participation in working groups; and are involved in research into the burden of food allergy in New Zealand. See our website for more information: www.allergy.org.nz

Alphapharm is Australia’s leading supplier by volume of prescription medicines to the Pharmaceutical Benefits Scheme (PBS). Alphapharm’s EpiPen® is the number one prescribed epinephrine auto-injector in Australia. Alphapharm supplies EpiPen® to Australians via the PBS, with two pens available on each prescription. Alphapharm is helping to improve the awareness of anaphylaxis in the community and improve access to epinephrine auto-injectors through the ‘Back to School’ information campaign. Alphapharm also sponsors Allergy & Anaphylaxis Australia to provide independent education for schools to create awareness and preparedness to manage anaphylaxis, as well as helping schools to recognise the need to have epinephrine auto-injectors and expertise to use them, in the event a person experiences anaphylaxis at school.

www.alphapharm.com.au

Cure. Care. Community. Asthma Australia and Asthma Foundations – the nations’ leading lung health charities
Together we seek a cure for asthma. Together we strive to improve the quality of life for people with asthma by providing accessible, affordable and evidence based services. Together to achieve our vision we raise funds ethically.
For over 50 years Asthma Australia and Asthma Foundations have been the leaders in asthma in health care and research. Asthma Australia and member Foundations deliver high quality support to people with asthma and their carers. As one of the country’s largest and most respected respiratory organisations, with offices and staff in every State and Territory of Australia, Asthma Australia delivers evidence-based preventative health strategies to over 200,000 people every year. We offer support, training, and resources to the primary health care sector and when treatment is required we ensure patients and their carers have the knowledge, information and power to be actively engaged in the decision making process. We fund vital basic science and population health research contributing to national and international understandings of asthma and how best to manage the disease.
1800 ASTHMA – asthmaaustralia.org.au

www.aussee.org

ausEE Inc. is an Australian charity and non-profit organisation dedicated to providing support and information to anyone diagnosed with or caring for someone with an Eosinophilic Gastrointestinal Disorder (EGID) including Eosinophilic Oesophagitis (EoE).

ausEE is committed to raising public awareness and supporting the medical community for further research into eosinophilic disorders in Australia. We have an active facebook group providing valuable support to parents and caregivers.

Please visit our website to order your free patient resources including children’s picture books on EoE, EGID medical brochures and patient information folders.

Australia: www.amsl.com.au
New Zealand: www.nzms.co.nz
At Australasian Medical and Scientific Ltd (AMSL) and New Zealand Medical and Scientific Ltd (NZMS) we deliver leading allergy solutions to allergists, dermatologists and other medical practitioners throughout Australia and New Zealand.

Our range includes Sub Lingual, Subcutaneous and Tablet Immunotherapy Vaccines; Skin Prick Test allergens; ready to use and open type Patch Test Systems; intradermal allergen tests for penicillin, amoxicillin and clavulanic acid; RhinoLight for treatment of allergic rhinitis; lancets and accessories.

Our range includes leading brands such as ALK Abello, SmartPractice, Lincoln Diagnostics and Diater. We pride ourselves on our experience and expertise in the field of allergy diagnosis and immunotherapy as well as our reliable and excellent service.
Baxter Healthcare develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Bio-Strategy is a team of highly qualified people, throughout Australia and New Zealand, who share a passion for Science. Representing world leading suppliers, Bio-Strategy brings our customers a complete range of solutions, from basic laboratory instrumentation through to advanced technology, covering applications in the Research, Healthcare, Biotechnology and Industrial Markets.

Our focus and commitment to our customers and suppliers, is key to Bio-Strategy’s excellence and success.

CSL has been the chosen national plasma fractionator of Australia since 1953, and New Zealand since 1963. Today CSL Behring works with Australian Governments, the Australian Red Cross Blood Service and the New Zealand Blood Service to deliver a world class and broad range of plasma-derived therapies specifically designed to meet the needs of healthcare professionals and patients in both these countries.

CSL Behring, through its research and development program, is committed to ensuring continued world class standards of quality, product yields, patient convenience and manufacturing efficiency in our broad portfolio of plasma-derived therapies. An example of this commitment is the use of modern manufacturing technologies for our products, such as large scale chromatography and the inclusion of at least two dedicated and complementary pathogen reduction steps in the manufacturing process of each product for Australia and New Zealand.

Diagnostic Solutions is a leading distributor of high quality, innovative automated systems for autoimmune diagnostic testing across Australia and New Zealand.

The Image Navigator® from Immuno Concepts is the most advanced automated IFA system today. With true sample traceability, fast positive / negative screening combined with interfacing to the CARIS™/DSR™ Systems using the DEESSE software the system can provide workflow streamlining capability for your laboratory.

Please visit our display to see a demonstration of the Image Navigator® and talk to us about how we can assist your laboratory with your Autoimmune testing needs.

Ego Pharmaceuticals is an Australian family owned and operated company who for more than 50 years have specialised in the manufacture of quality skincare products such as market leaders ‘QV’, ‘Sunsense’, ‘Pinetarsol’, ‘DermAid’ and ‘Moov’. The QV range of gentle moisturisers and cleansers has been scientifically formulated for those who suffer from dry or sensitive skin conditions. The entire QV range is free from colour, fragrance, propylene glycol, lanolin and its derivatives making it ideal for the most sensitive skin types.

ESL Biosciences supplies high quality, automated in-vitro diagnostic instruments and reagents and provides full training in their use throughout Australasia.

With over 25 years of experience in the niche field of autoimmunity we offer a comprehensive range of products from Euroimmun, a world leader in autoimmune diagnostics. Assays include (but are not limited to) those for Rheumatology, Autoimmune Hepatitis, PBC and Vasculitis. Others include test kits...
for the determination of Gluten sensitivity, antibody test kits for Autoimmune Mediated Diabetes markers and Autoantibodies in Paraneoplastic Neurological Syndromes (PNS). ESL Biosciences also presents a range of automated systems to the laboratory.

IDFA is governed by a Board of Directors which includes two leading Australian Immunologists (Paediatric and Adult). IDFA is a member of IPOPI (International Patient Organisation for Primary Immunodeficiencies) and has representation on the IPOPI Board. IDFA welcomes membership from Immunologists and other Health Professionals.

For further information, email christine.jeffery@idfa.org.au, call 0409 945 114 or visit our website.

In Vitro Technologies

In Vitro Technologies specialises in the sale and support of scientific, diagnostic, medical and related products in Australian and New Zealand. The Diagnostics Division represents leading global niche market companies in biochemistry, autoimmunity, immunology, haematology, microbiology, and point of care.

In Vitro Technologies marketing partners include Immco Diagnostics. Immco develops and distributes autoimmune disease products to labs worldwide, offering a comprehensive selection of autoimmune diagnostics under the leading brands: ImmuGlo™, ImmuLisa™, and ImmuBlot™. Immco assay development led to the first immunofluorescence assay for diagnosing coeliac disease. Immco is continually expanding their product offering, providing the total solution in autoimmunity. Ph: 1300 552 003
LINK Healthcare is a privately owned Australian-based specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of a vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand.

LINK provides exceptional sales and marketing infrastructure and is partnered with major pharmaceutical & medical device companies from around the world, allowing the company to offer a unique and substantial portfolio.

LINK Pharma has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anesthesia, Anti-infective, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda’s products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda’s well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to call to access the members’ important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda’s products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda’s well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to call to access the members’ important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda’s products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda’s well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to call to access the members’ important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda’s products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda’s well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to call to access the members’ important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda’s products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda’s well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to call to access the members’ important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.
for prolonged moisturization of dry nasal passages. NeilMed’s 
NasaMist® buffered, preservative free nasal spray, isotonic and 
hypertonic available. NasaDrops Ampoules with Aspirators Saline 
ampoules for stuffy, congested or dry noses for babies, children & 

Good Food, Good Life

www.nestle-hcp.com.au
www.nestlehealthscience.com.au

Nestlé is the world’s leading Nutrition, Health and Wellness 
company. Through integrating scientific and research expertise, 
Nestlé Nutrition aims to pioneer the development and application 
of evolving science to help children develop to their full potential 
plus create a new role for nutrition in disease prevention and 
management. Nestlé Health Science & Nestlé Nutrition offer 
both high quality nutrition for children in the crucial first years of 
life & nutritional solutions for people with specific dietary needs 
related to illnesses, disease states or the special challenges of 
different life stages.

As a long time partner of ASCIA please come and visit us during 
this year’s meeting to find out more about our product range.

Novartis is a world leader in the research, development and 
supply of medicines to prevent and cure diseases, ease suffering 
and enhance quality of life.

Headquartered in Basel, Switzerland, we employ approximately 
100,000 people worldwide and operate in over 140 countries.

Novartis offers a wide range of healthcare products through our 
Pharmaceuticals, Vaccines and Diagnostics, Sandoz and 
Consumer Health Divisions. Our medicines treat some of the most 
serious conditions confronting healthcare professionals and their 
patients in the areas of cardiovascular disease, oncology, 
immunology, infectious diseases and ophthalmics.

In Australia Novartis employs more than 900 people, and invests 
over AUD $30 million annually in local research.

Octapharma specialises in the development and production of 
human proteins derived from plasma and recombinant 
technologies. Using cutting-edge purification and viral inactivation 
techniques we live by our mission of “for the safe and optimal use 
of human proteins.”

We provide life saving therapies to our patients worldwide in the 
treatment of multifarious diseases in Haematology, Immunotherapy, 
Intensive Care and Emergency Medicine.

Octapharma operates and manufactures products to the standards 
of quality and safety required by regulatory authorities globally. 
Please contact Octapharma Australia for more information.

PathWest Laboratory Medicine WA is committed to providing 
excellence and innovation in pathology testing, teaching and 
research, positively contributing to the health and wellbeing of the 
community. We have a proud service record and as Western 
Australia’s leading referral pathology laboratory we respond to the 
needs of virtually every medical practitioner in the State.

Our active teaching, clinical research and pathology development 
programs assist not only in enhancing diagnostic accuracy but 
also in improving the understanding of disease processes and of 
clinical care.
Shire

www.shireaustralia.com.au

As one of the leading specialty biopharmaceutical companies, Shire focuses on a single purpose: to enable people with life-altering conditions to lead better lives. Shire’s Rare Diseases Business Unit focuses on research, developing and providing treatments that enhance the quality of life of patients suffering from rare diseases. Established in 2008, Shire Australia offers products in Fabry and Gaucher Diseases and Hereditary Angioedema. Shire also provides products for Hyperphosphataemia in CKD5D, Essential Thrombocythaemia and mild to moderate active Ulcerative Colitis. Address: Level 6, 123 Epping Road, North Ryde, NSW, 2113. Phone: +61280194400; www.shireaustralia.com.au; Customer Services: 1800012612 or enquiriesaustralia@shire.com

Stallergenes

www.stallergenes.com

For over half a century Stallergenes has been a leader and pioneer in allergen immunotherapy. With a strong commitment to research and development, Stallergenes dedicates close to 20% of its turnover each year to the development of innovative and evidence-based treatments.

Locally, Stallergenes Australia is dedicated to supporting the Australasian allergist community in addressing the significant unmet need of patients with moderate to severe allergic respiratory disease. Our investment to this cause is evident through the consistent sponsorship, support and grants we provide along with delivering the only TGA and Medsafe registered AIT treatments on the ANZ market.

Takeda

www.takedaaustralia.com.au

Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan and an industry leader. Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine. Takeda’s in-house ethical drugs are marketed in around 90 countries worldwide and focus on gastrointestinal, respiratory, oncology, central nervous system, cardiovascular and diabetes. Takeda Australia aims to launch numerous products from the impressive Takeda pipeline, supplemented by additional in-licensed products, in the next few years.

TAMS


Education, Advocacy, Support, Research

The Australasian Mastocytosis Society (TAMS), formed in 2011 is working to;

- Provide a network of support for patients living with Mastocytosis or a Mast Cell Activation Disorder (MCAD) and their carers
- Connect patients to medical practitioners and specialists with knowledge of Mastocytosis and MCAD
- Link together with similar associations worldwide to collectively gather research data, share resources and knowledge in the hope of greater understanding, treatment practices, medications and overall improved health outcomes for those living with Mastocytosis or MCAD.

ViroPharma

www.viropharma.com

ViroPharma is an international biopharmaceutical company committed to developing and commercialising innovative products that address unmet medical needs.

ViroPharma focuses on providing products to healthcare professionals that support patients with serious conditions, including disease caused by C1 esterase inhibitor deficiency.

ViroPharma is dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.

For further information, please contact ViroPharma Customer Service on:

Toll-free telephone: 1800 767 232
Email: au.customerservice@viropharma.com

The advertising space for ASCIA 2014 (see opposite page) has been supported by

CSL Behring

a Diamond Sponsor of ASCIA in 2013 and a Founding Sponsor of AIFA.
25th annual scientific meeting
of the Australasian Society of Clinical Immunology and Allergy (ASCIA)

Wednesday 10th to Saturday 13th September 2014
Melbourne Convention and Exhibition Centre
Victoria Australia

Registration and abstract submission will be available by late April 2014 at www.ascia2014.com.au

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand.
24 years of ASCIA Annual Scientific Meetings 1990 – 2013

1990 1st ASCIA ASM – Melbourne VIC (Hilton on the Park, April 29 - May 1)
1991 2nd ASCIA ASM – Perth, WA (Burswood Hotel, December 1-3)
1992 3rd ASCIA ASM – Cairns, QLD (Hilton Hotel, September 13-15)
1993 4th ASCIA ASM – Sydney, NSW (Darling Harbour, April 29 – May 1)
1994 5th ASCIA ASM – Canberra, ACT (Lakeside Hotel, December 2-5)
1995 6th ASCIA ASM – Sydney, NSW (Regent Hotel, October 30-November 3) with TPAIS
1996 7th ASCIA ASM – Adelaide, SA (Hyatt Hotel, December 5-7)
1997 8th ASCIA ASM – Wellington, NZ (Convention Centre, April 5-8) held with TSANZ
1998 9th ASCIA ASM – Brisbane, QLD (Sheraton Hotel, August 28-30)
1999 10th ASCIA ASM – Uluru, NT (Ayers Rock Resort, September 24-27)
2000 11th ASCIA ASM – Sydney, NSW (Convention Centre, October 15-20)
   (held as part of the 17th World Allergy Congress)
2001 12th ASCIA ASM – Perth, WA (Sheraton Hotel, September 28-30)
2002 13th ASCIA ASM – Adelaide, SA (Hilton Hotel, September 27-29)
2003 14th ASCIA ASM – Melbourne, VIC (Sheraton Southgate Hotel, September 10-12)
2004 15th ASCIA ASM – Gold Coast, QLD (Marriott Hotel, September 8-10)
2005 16th ASCIA ASM – Queenstown, NZ (Millennium Hotel, August 31 - September 2)
2006 17th ASCIA ASM – Sydney, NSW (Manly Pacific Hotel, September 7-9)
2007 18th ASCIA ASM – Fremantle, WA (Esplanade Hotel, November 14-16)
2008 19th ASCIA ASM – Melbourne (Park Hyatt Hotel, November 12-14)
2009 20th ASCIA ASM – Adelaide, SA (Adelaide Convention Centre, September 16-18)
2010 21st ASCIA ASM – Gold Coast, QLD (Gold Coast Convention & Exhibition Centre, September 1-4)
2011 22nd ASCIA ASM – Sydney, NSW (Sydney Convention & Exhibition Centre, Darling Harbour, September 6-10)
2012 23rd ASCIA ASM – Wellington, New Zealand (Wellington Town Hall, September 5-7)
2013 24th ASCIA ASM – Perth, Western Australia (Perth Convention and Exhibition Centre, September 10-14)